Merck KGaA Collaborates with Iktos for its Artificial Intelligence (AI) Technology

Shots:

• Merck KGaA enters into an agreement with Iktos to develop therapies using Iktos’ AI technology for three drug discovery projects
• The focus of the agreement is to develop and advance its drug discovery techniques with the usage of Iktos’ technology enabled with AI solutions in multiple therapy areas
• Iktos’ AI technology is based on deep generative models providing drug discovery techniques by designing virtual molecules for treating diseases, also used in image processing & automatic translation. On Dec’18, Merck also collaborated with Cyclica for its AI-augmented proteome screening, Ligand Express

Click here to read full press release/ article | Ref: PRNewswire | Image: Teller Report